C-Terminal Proarginine Vasopressin is Associated with Disease Outcome and Mortality, but not with Delayed Cerebral Ischemia in Critically Ill Patients with an Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study

What Was Tested

The paper reports a study of Vasopressin, published as an observational study.

The primary aim was to investigate the relationship between CT-proAVP and poor functional outcome at 1 year (Glasgow Outcome Scale score 1-3) in a multivariable logistic regression model adjusted for WFNS and APACHE IV scores.

Why It Was Studied

The researchers assessed the ability of C-terminal proarginine vasopressin (CT-proAVP) to predict disease outcome, mortality, and delayed cerebral ischemia (DCI) in critically ill patients with aSAH compared with the World Federation of Neurological Surgeons (WFNS) score and Acute Physiological and Chronic Health Evaluation IV (APACHE IV) model.

How the Study Was Run

C-terminal proarginine vasopressin was collected on admission in this single-center, prospective, observational cohort study.

Secondary aims were mortality and DCI.

The multivariable logistic regression model for DCI was also adjusted for the modified Fisher scale.

What Was Measured

The researchers assessed the ability of C-terminal proarginine vasopressin (CT-proAVP) to predict disease outcome, mortality, and delayed cerebral ischemia (DCI) in critically ill patients with aSAH compared with the World Federation of Neurological Surgeons (WFNS) score and Acute Physiological and Chronic Health Evaluation IV (APACHE IV) model.

Topics PubMed links to this paper include Subarachnoid Hemorrhage, Critical Illness, Cerebral Infarction, Brain Ischemia, Cohort Studies and Vasopressins.

Author keywords: CT-proAVP, Prognosis and aSAH.

What This Means in Plain Language

This is an observational study of Vasopressin.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Neurocritical care), a journal based in United States.

More context: the Vasopressin compound page, all human trials.